多发性硬化症中平滑追踪功能障碍的定量评估。
Quantification of smooth pursuit dysfunction in multiple sclerosis.
机构信息
Dept. of Neurosciences, University of California San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.
NeuroFit, Mountain View, CA, USA.
出版信息
Mult Scler Relat Disord. 2021 Sep;54:103073. doi: 10.1016/j.msard.2021.103073. Epub 2021 Jun 5.
BACKGROUND
Smooth pursuit dysfunction is common in MS, but rarely quantified and may be missed on exam.
METHODS
NeuroFitONE™ smooth pursuit performance measures were compared between MS (n = 20) and healthy control (n = 19) participants.
RESULTS
Compared to controls, MS patients had lower proportion of smooth pursuit (0.63 vs. 0.73; p = 0.047), increased directional (10.1 vs. 8°; p = 0.014) and speed noise (4.3 vs. 3.1°/sec; p = 0.021) and reduced initiation acceleration (96.83 vs. 115.33°/sec; p = 0.061). Significant univariate correlations with clinical scores (EDSS, T25-FW) were observed.
CONCLUSION
Smooth pursuit dysfunction in MS can be readily quantified and distinguishes MS eyes from healthy controls.
背景
平滑追踪障碍在多发性硬化症中很常见，但很少被量化，在检查中可能会被忽略。
方法
比较了 NeuroFitONE™ 平滑追踪表现测量在多发性硬化症（n=20）和健康对照组（n=19）参与者之间的差异。
结果
与对照组相比，多发性硬化症患者的平滑追踪比例较低（0.63 对 0.73；p=0.047），方向偏差较大（10.1 对 8°；p=0.014），速度噪声较大（4.3 对 3.1°/秒；p=0.021），启动加速度较低（96.83 对 115.33°/秒；p=0.061）。与临床评分（EDSS、T25-FW）有显著的单变量相关性。
结论
多发性硬化症中的平滑追踪障碍可以很容易地被量化，并将多发性硬化症患者的眼睛与健康对照组区分开来。
Zotero 插件